Terms: = Leukemia AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
201 results:
1. On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation.
Wang X; Wang Y; Chen J; Wang Q; Liu Z; Yin Y; Yang T; Shen T; Sa Y
Sci Rep; 2024 May; 14(1):10114. PubMed ID: 38698063
[TBL] [Abstract] [Full Text] [Related]
2. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.
Valdez BC; Yuan B; Murray D; Ramdial JL; Popat U; Nieto Y; Andersson BS
Oncotarget; 2024 Mar; 15():220-231. PubMed ID: 38484153
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of PRMT5/MEP50 Arginine Methyltransferase Activity Causes Cancer Vulnerability in NDRG2
Ichikawa T; Suekane A; Nakahata S; Iha H; Shimoda K; Murakami T; Morishita K
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474089
[TBL] [Abstract] [Full Text] [Related]
4. Bacterial heat shock protein genes during induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Dunn KA; MacDonald E; MacDonald T; Kulkarni K
Future Oncol; 2024 Jan; 20(1):17-23. PubMed ID: 38189148
[No Abstract] [Full Text] [Related]
5. Co-targeting hsp90 alpha and CDK7 overcomes resistance against hsp90 inhibitors in BCR-ABL1+ leukemia cells.
Vogt M; Dienstbier N; Schliehe-Diecks J; Scharov K; Tu JW; Gebing P; Hogenkamp J; Bilen BS; Furlan S; Picard D; Remke M; Yasin L; Bickel D; Kalia M; Iacoangeli A; Lenz T; Stühler K; Pandyra AA; Hauer J; Fischer U; Wagener R; Borkhardt A; Bhatia S
Cell Death Dis; 2023 Dec; 14(12):799. PubMed ID: 38057328
[TBL] [Abstract] [Full Text] [Related]
6. A Coumarin-Imidazothiadiazole Derivative, SP11 Abrogates Tumor Growth by Targeting hsp90 and Its Client Proteins.
Nirgude S; Shahana M V ; Ravindran F; Kumar S; Sharma S; Mahadeva R; Mhatre A; Karki SS; Choudhary B
Molecules; 2023 Jul; 28(13):. PubMed ID: 37446888
[TBL] [Abstract] [Full Text] [Related]
7. Heat shock factor 1 is a promising therapeutic target against adult T-cell leukemia.
Ishikawa C; Mori N
Med Oncol; 2023 May; 40(6):172. PubMed ID: 37165174
[TBL] [Abstract] [Full Text] [Related]
8. Role of Ganetespib, an hsp90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice.
Youssef ME; Cavalu S; Hasan AM; Yahya G; Abd-Eldayem MA; Saber S
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902446
[TBL] [Abstract] [Full Text] [Related]
9. Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid leukemia Cell Lines.
Alves R; Santos D; Jorge J; Gonçalves AC; Catarino S; Girão H; Melo JB; Sarmento-Ribeiro AB
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770876
[TBL] [Abstract] [Full Text] [Related]
10. Heat shock protein 90 inhibitors induce cell differentiation via the ubiquitin-dependent aurora kinase A degradation in a MPLW515L mouse model of primary myelofibrosis.
Wang F; Zhang H; He B; Liu Z; Wu X; Liu Y; Xu X; Gou X; Wang H; Yang Q
Hematol Oncol; 2023 Aug; 41(3):474-486. PubMed ID: 36422297
[TBL] [Abstract] [Full Text] [Related]
11. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
[TBL] [Abstract] [Full Text] [Related]
12. Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid leukemia.
Katagiri S; Chi S; Minami Y; Fukushima K; Shibayama H; Hosono N; Yamauchi T; Morishita T; Kondo T; Yanada M; Yamamoto K; Kuroda J; Usuki K; Akahane D; Gotoh A
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563085
[TBL] [Abstract] [Full Text] [Related]
13. Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid leukemia.
Bruserud Ø; Reikvam H; Brenner AK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163998
[TBL] [Abstract] [Full Text] [Related]
14. Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.
Ichikawa T; Sugamoto K; Matsuura Y; Kunitake H; Shimoda K; Morishita K
Cancer Sci; 2022 Apr; 113(4):1406-1416. PubMed ID: 35100463
[TBL] [Abstract] [Full Text] [Related]
15. Arsenite-loaded albumin nanoparticles for targeted synergistic chemo-photothermal therapy of HCC.
Zhang K; Li D; Zhou B; Liu J; Luo X; Wei R; Wang L; Hu X; Su Z; Lin H; Gao J; Shan H
Biomater Sci; 2021 Dec; 10(1):243-257. PubMed ID: 34846385
[TBL] [Abstract] [Full Text] [Related]
16. The Antileukemic Effect of Xestoquinone, A Marine-Derived Polycyclic Quinone-Type Metabolite, Is Mediated through ROS-Induced Inhibition of HSP-90.
Wang KC; Lu MC; Hsu KC; El-Shazly M; Shih SP; Lien ST; Kuo FW; Yang SC; Chen CL; Yang YSH
Molecules; 2021 Nov; 26(22):. PubMed ID: 34834129
[TBL] [Abstract] [Full Text] [Related]
17. Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance.
Fleischmann M; Fischer M; Schnetzke U; Fortner C; Kirkpatrick J; Heidel FH; Hochhaus A; Scholl S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831215
[TBL] [Abstract] [Full Text] [Related]
18. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in leukemia Therapy.
Takahashi S
Acta Haematol; 2022; 145(2):113-121. PubMed ID: 34673646
[TBL] [Abstract] [Full Text] [Related]
19. Effect of hsp90aB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
[TBL] [Abstract] [Full Text] [Related]
20. Insight into Bortezomib Focusing on Its Efficacy against P-gp-Positive MDR leukemia Cells.
Kyca T; Pavlíková L; Boháčová V; Mišák A; Poturnayová A; Breier A; Sulová Z; Šereš M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071136
[TBL] [Abstract] [Full Text] [Related]
[Next]
